Xadago(safinamide)
Safinamide, Xadago (safinamide) is a small molecule pharmaceutical. Safinamide was first approved as Xadago on 2015-02-23. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against amine oxidase [flavin-containing] B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Safinamide, Xadago (discontinued: Safinamide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Safinamide mesylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XADAGO | MDD US Operations | N-207145 RX | 2017-03-21 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xadago | New Drug Application | 2024-10-10 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 2 | 1 | 1 | 4 |
| Chronic pain | D059350 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyskinesias | D020820 | — | G24 | — | — | 1 | — | — | 1 |
| Drug-induced dyskinesia | D004409 | EFO_1000904 | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | 1 | — | — | — | 1 |
| Multiple system atrophy | D019578 | — | — | — | 1 | — | — | — | 1 |
| Atrophy | D001284 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Safinamide |
| INN | safinamide |
| Description | Safinamide is an amino acid amide. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 133865-89-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL396778 |
| ChEBI ID | — |
| PubChem CID | 131682 |
| DrugBank | DB06654 |
| UNII ID | 90ENL74SIG (ChemIDplus, GSRS) |
Target
Agency Approved
MAOB
MAOB
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xadago – Supernus Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,067 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
444 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use